Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 11/20 | 0.70 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266106 | 1.00 | SLC34A2 (0.70) | SLC34A2FLT3MEN1KMT2ANPC1 | |
| SCHEMBL266105 | 1.00 | SLC34A2 (0.70) | SLC34A2FLT3MEN1KMT2ANPC1 | |
| SCHEMBL270196 | 0.99 | SLC34A2 (0.68) | SLC34A2FLT3MEN1KMT2ANPC1 | |
| SCHEMBL274541 | 0.99 | SLC34A2 (0.68) | SLC34A2FLT3MEN1KMT2ANPC1 | |
| SCHEMBL270195 | 0.99 | SLC34A2 (0.68) | SLC34A2FLT3MEN1KMT2ANPC1 | |
| SCHEMBL274309 | 0.91 | SLC34A2 (0.72) | SLC34A2FLT3MEN1KMT2ANPC1 | |
| SCHEMBL266699 | 0.91 | SLC34A2 (0.72) | SLC34A2FLT3MEN1KMT2ANPC1 | |
| SCHEMBL266700 | 0.91 | SLC34A2 (0.72) | SLC34A2FLT3MEN1KMT2ANPC1 | |
| SCHEMBL265859 | 0.88 | SLC34A2 (0.77) | SLC34A2FLT3MEN1KMT2ANPC1 | |
| SCHEMBL274073 | 0.88 | SLC34A2 (0.77) | SLC34A2FLT3MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | SLC34A1, SLC34A2, SLC20A2 | SLC34A2 2/4885FLT3 2535/4885MEN1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.